CIK 1791827
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 91.17% | 34 |
| Health Care Equipment & Supplies | 4.18% | 5 |
| Health Care Providers & Services | 1.59% | 3 |
| Insurance | 0.99% | 3 |
| Unclassified | 0.80% | 2 |
| Software & IT Services | 0.51% | 1 |
| Chemicals | 0.39% | 2 |
| Leisure Products | 0.21% | 1 |
| Life Sciences Tools & Services | 0.18% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Health Care | 38.62% |
| 2 | ORKA | Oruka Therapeutics, Inc. | Health Care | 9.55% |
| 3 | CGON | CG Oncology, Inc. | Health Care | 9.32% |
| 4 | JBIO | Jade Biosciences, Inc. | Health Care | 5.76% |
| 5 | CATX | Perspective Therapeutics, Inc. | Health Care | 5.22% |
| 6 | ELVN | Enliven Therapeutics, Inc. | Health Care | 3.44% |
| 7 | CNTX | Context Therapeutics Inc. | Health Care | 2.66% |
| 8 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Health Care | 2.20% |
| 9 | RGEN | REPLIGEN CORP | Health Care | 1.96% |
| 10 | PVLA | PALVELLA THERAPEUTICS, INC. | Health Care | 1.89% |
50/52 names classified · sector 99.2% of weight · industry 99.2% · mkt cap 96.7%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 99.2% of the book is sector-classified (unclassified names shown, never dropped).
Only 12% of book weight classified — the grid is NOT representative of the whole book.
Classified: 11.8% of book weight (16/52 names) · unclassified 88.2%: DNTH, ORKA, CGON, JBIO, CATX, ELVN, CNTX, PVLA, AKTS, VIR +26 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | DNTHDIANTHUS THERAPEUTICS INC | 4,208,368 | $361M | 38.6% | ADD 100% |
| 2 | ORKAORUKA THERAPEUTICS INC | 1,520,848 | $89M | 9.5% | ADD 130% |
| 3 | CGONCG ONCOLOGY INC | 1,288,948 | $87M | 9.3% | TRIM −12% |
| 4 | JBIOJADE BIOSCIENCES INC | 2,801,416 | $54M | 5.8% | ADD 100% |
| 5 | CATXPERSPECTIVE THERAPEUTICS INC | 12,099,998 | $49M | 5.2% | ADD 277% |
| 6 | ELVNENLIVEN THERAPEUTICS INC | 800,000 | $32M | 3.4% | ADD 470% |
| 7 | CNTXCONTEXT THERAPEUTICS INC | 9,996,534 | $25M | 2.7% | ADD 82% |
| 8 | TEVATEVA PHARMACEUTICAL INDS LTD | 650,100 | $21M | 2.2% | ADD 56% |
| 9 | RGENREPLIGEN CORP | 155,600 | $18M | 2.0% | ADD 209% |
| 10 | PVLAPALVELLA THERAPEUTICS INC | 140,000 | $18M | 1.9% | ADD 625% |
| 11 | AKTSAKTIS ONCOLOGY INC | 937,132 | $17M | 1.8% | NEW |
| 12 | MDTMEDTRONIC PLC | 200,000 | $17M | 1.8% | ADD 86% |
| 13 | VIRVIR BIOTECHNOLOGY INC | 1,569,300 | $15M | 1.6% | NEW |
| 14 | IMUXIMMUNIC INC | 7,369,352 | $14M | 1.5% | ADD 57% |
| 15 | DXCMDEXCOM | 190,000 | $12M | 1.2% | NEW |
| 16 | EHCENCOMPASS HEALTH CORP | 84,000 | $8M | 0.9% | ADD 166% |
| 17 | BSXBOSTON SCIENTIFIC CORP | 120,000 | $7M | 0.8% | ADD 5% |
| 18 | TENXTENAX THERAPEUTICS INC | 481,868 | $7M | 0.7% | NEW |
| 19 | KPTIKARYOPHARM THERAPEUTICS INC | 927,482 | $6M | 0.7% | ADD 589% |
| 20 | HUMHUMANA INC | 25,000 | $6M | 0.6% | NEW |
| 21 | PHATPHATHOM PHARMACEUTICALS INC | 498,780 | $6M | 0.6% | ADD 142% |
| 22 | GILDGILEAD SCIENCES INC | 40,000 | $5M | 0.6% | NEW |
| 23 | MSLESATELLOS BIOSCIENCE INC | 775,538 | $5M | 0.6% | NEW |
| 24 | TEMTEMPUS AI INC | 90,000 | $5M | 0.5% | NEW |
| 25 | SCYXSCYNEXIS INC | 4,163,320 | $4M | 0.4% | ADD 100% |
| 26 | ICLRICON PLC | 32,000 | $4M | 0.4% | TRIM −3% |
| 27 | NTRANATERA INC | 18,000 | $4M | 0.4% | ADD 53% |
| 28 | GPCRSTRUCTURE THERAPEUTICS INC | 78,000 | $3M | 0.4% | NEW |
| 29 | CRVSCORVUS PHARMACEUTICALS INC | 230,000 | $3M | 0.4% | NEW |
| 30 | HIMSHIMS & HERS HEALTH INC | 125,000 | $3M | 0.3% | NEW |
| 31 | GMABGENMAB A/S | 100,000 | $3M | 0.3% | ADD 9% |
| 32 | CORTCORCEPT THERAPEUTICS INC | 60,000 | $3M | 0.3% | ADD 173% |
| 33 | CNCCENTENE CORP DEL | 70,000 | $2M | 0.2% | TRIM −41% |
| 34 | NTLAINTELLIA THERAPEUTICS INC | 150,000 | $2M | 0.2% | NEW |
| 35 | PTONPELOTON INTERACTIVE INC | 400,000 | $2M | 0.2% | NEW |
| 36 | ODDODDITY TECH LTD-CL A | 140,000 | $2M | 0.2% | NEW |
| 37 | AVRANTERIS TECHNOLOGIES GLOBAL | 300,000 | $2M | 0.2% | NEW |
| 38 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 100,000 | $2M | 0.2% | NEW |
| 39 | KVUEKENVUE INC | 100,000 | $2M | 0.2% | TRIM −57% |
| 40 | PODDINSULET CORP | 10,000 | $2M | 0.2% | NEW |
| 41 | CRLCHARLES RIV LABS INTL INC | 10,000 | $2M | 0.2% | NEW |
| 42 | RVMDREVOLUTION MEDICINES INC | 15,000 | $1M | 0.2% | NEW |
| 43 | ABVXABIVAX SA | 10,000 | $1M | 0.1% | NEW |
| 44 | ABUSARBUTUS BIOPHARMA CORP | 250,000 | $1M | 0.1% | NEW |
| 45 | UNHUNITEDHEALTH GROUP INC | 3,800 | $1M | 0.1% | NEW |
| 46 | ABTABBOTT LABS | 10,000 | $907,900 | 0.1% | NEW |
| 47 | BBOTBRIDGEBIO ONCOLOGY THERAPEUTIC | 87,706 | $761,288 | 0.1% | NEW |
| 48 | BBIOBRIDGEBIO PHARMA INC | 10,000 | $711,100 | 0.1% | NEW |
| 49 | ACADACADIA PHARM | 25,934 | $579,754 | 0.1% | TRIM −76% |
| 50 | LEGNLEGEND BIOTECH CORP | 15,000 | $352,800 | 0.0% | NEW |
| 51 | SVRASAVARA INC | 50,000 | $262,000 | 0.0% | NEW |
| 52 | TRVITREVI THERAPEUTICS INC | 13,320 | $171,096 | 0.0% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| DNTHDIANTHUS THERAPEUTICS INC | 2.9M | 1.7M | 1.7M | 3.2M | 2.1M | 4.2M | $361M |
| ORKAORUKA THERAPEUTICS INC | 352K | 352K | 352K | 660K | 660K | 1.5M | $89M |
| CGONCG ONCOLOGY INC | 1.1M | 981K | 1.5M | 1.6M | 1.5M | 1.3M | $87M |
| JBIOJADE BIOSCIENCES INC | — | — | 1.1M | 1.1M | 1.4M | 2.8M | $54M |
| CATXPERSPECTIVE THERAPEUTICS INC | 2.7M | 2.2M | 1.9M | 3.0M | 3.2M | 12.1M | $49M |
| ELVNENLIVEN THERAPEUTICS INC | — | 11K | 11K | 140K | 140K | 800K | $32M |
| CNTXCONTEXT THERAPEUTICS INC | 7.5M | 7.5M | 7.5M | 9.0M | 5.5M | 10.0M | $25M |
| TEVATEVA PHARMACEUTICAL INDS LTD | — | 481K | 690K | 510K | 417K | 650K | $21M |
| RGENREPLIGEN CORP | — | — | 107K | 23K | 50K | 156K | $18M |
| PVLAPALVELLA THERAPEUTICS INC | — | — | — | — | 19K | 140K | $18M |
| AKTSAKTIS ONCOLOGY INC | — | — | — | — | — | 937K | $17M |
| MDTMEDTRONIC PLC | — | — | — | 191K | 108K | 200K | $17M |
| VIRVIR BIOTECHNOLOGY INC | — | — | — | — | — | 1.6M | $15M |
| IMUXIMMUNIC INC | 8.0M | 4.5M | 5.6M | 4.7M | 4.7M | 7.4M | $14M |
| DXCMDEXCOM | 318K | 180K | 211K | — | — | 190K | $12M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
